Gaxos.ai Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Gaxos.ai describes its business as developing AI applications for gaming and health. Its gaming platform includes games launched in 2023, with additional games and AI products planned.
Financial results and position
| Metric | Q1 2024 / March 31, 2024 | Comparable period / December 31, 2023 |
|---|---|---|
| Revenue | $19 | $0 in Q1 2023 |
| Operating expenses | $1,043,858 | $1,542,332 in Q1 2023 |
| Operating loss | $1,043,839 | $1,542,332 in Q1 2023 |
| Net loss | $912,145; $0.91 per share | $1,536,031; $1.64 per share in Q1 2023 |
| Comprehensive loss | $1,011,560 | $1,517,875 in Q1 2023 |
| Cash and short-term investments | $3,312,277 cash; $2,092,078 investments | $1,024,710 cash; $2,592,689 investments at December 31, 2023 |
| Working capital | $5,251,505 | Not stated as a comparative figure |
| Total assets / liabilities | $5,981,312 / $513,773 | $3,695,946 / $270,036 at December 31, 2023 |
| Operating cash flow | $(1,099,417) | $(933,858) in Q1 2023 |
Revenue was negligible, so a meaningful revenue margin is not available. The filing reports no debt balance; liabilities shown are accounts payable and accrued expenses. Cash plus short-term investments totaled approximately $5.4 million at quarter-end.
Material changes and financing
- Net loss declined 40.6% year over year, primarily alongside lower general and administrative expense and higher other income. Operating expenses fell 32.3%; lower stock-based compensation and professional fees were partly offset by higher research and development and other G&A costs.
- Other income was $131,694, including a $119,715 realized gain on short-term investments. Short-term investments also had an unrealized loss in Q1 2024.
- Operating cash use increased from $933,858 to $1,099,417, despite the smaller net loss; the filing cites, among other items, a $335,781 increase in prepaid expenses and other current assets.
- A March private placement raised $3,499,484 gross and $3,056,984 net, according to the notes. Financing cash flow was $3,037,382, including the share repurchase. The offering included 108,000 common shares and warrants to purchase substantial additional shares, including 520,367 pre-funded warrants and 1,256,734 Series A and B warrants. Additional placement-agent warrants were issued.
- The company completed a 1-for-12 reverse stock split on March 7, 2024. Per-share and share-count figures in the financial statements reflect the split.
Outlook, risks, and other disclosures
- Management expects continued operating losses while it implements its growth strategy, and says existing working capital and cash should meet operating needs and debt requirements for the next 12 months from the report’s issuance. It also states that execution of its longer-term plan will require significant capital and that additional financing may not be available on favorable terms, or at all.
- Management expected to launch its AI solution for game developers in Q2 2024 and an AI-powered health product in the second half of 2024. Research and development expense is expected to increase as development advances. These are forward-looking plans, not reported results.
- The company reported that Nasdaq notified it in January that it had not regained minimum-bid-price compliance; following an appeal, it received notice on March 22 that it had regained compliance.
- Risks include financing needs, sustained losses, attracting and retaining users and advertisers, competition, product execution, intellectual property, regulation, and key-personnel retention. The company reported no material legal proceedings and no material changes to previously disclosed risk factors. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting.
Investor facts to verify
- Confirm the post-quarter launch and commercial progress of the gaming AI solution and planned health product; Q1 revenue was only $19.
- Assess cash burn and runway against the company’s stated 12-month liquidity expectation and its acknowledged need for future financing.
- Review potential dilution from the private-placement warrants, placement-agent warrants, options, and any subsequent exercises or share issuances.
- Reconcile reported investment-related figures: the statements show a $99,415 unrealized loss, while a note describes a $99,015 loss; the filing text does not provide a clear reconciliation.
- Check expense comparisons: MD&A states operating expenses decreased by $498,493, while the reported totals imply a $498,474 decrease.